STOCK TITAN

If You Invested in CARGO Therapeutics, Inc. (CRGX)

Healthcare · Biotechnology · NASDAQ
See the CRGX overview
CRGX has not traded since Aug 18, 2025. Its last close was $4.47, so every figure on this page ends there and the 1, 5 and 10 year results count back from that close.
$1,000 invested 1 Year Before Its Last Close
$255
-74.5% price return
-74.5% with dividends reinvested
Bought on Aug 19, 2024 at $17.50 split-adjusted
$1,000 invested 5 Years Before Its Last Close
N/A
Our prices start Nov 10, 2023
$1,000 invested 10 Years Before Its Last Close
N/A
Our prices start Nov 10, 2023

What $1,000 or $10,000 in CRGX Was Worth at Its Last Close

Real historical value by amount invested and how long before the last close
If you invested 1 year before 5 years before 10 years before Since Nov 10, 2023
$1,000 $255 -74% — — $308 -69%
$10,000 $2,554 -74% — — $3,076 -69%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2025-08-18. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for CRGX

$1,000 Investment Over Time

CRGX vs S&P 500

Year-by-Year Returns

CRGX annual performance
Year Start Price End Price Annual Return Cumulative
2023Nov 10 to Dec 29 $14.53 $23.15 +59.3% +59.3%
2024 $23.15 $14.42 -37.7% -0.8%
2025Dec 31, 2024 to Aug 18 $14.42 $4.47 -69.0% -69.2%

About CARGO Therapeutics, Inc.

Healthcare · NASDAQ

CARGO Therapeutics, Inc. (CRGX) was a clinical-stage biotechnology company whose work centered on the research and development of cell therapies for cancer patients. According to multiple company disclosures, CARGO described itself as a biotechnology company focused on, and positioned to advance, next-generation, potentially curative cell therapies that directly address limitations of approved cell therapies such as limited durability of effect, safety concerns and unreliable supply.

The company’s activities were classified under research and development in biotechnology within the broader professional, scientific, and technical services sector. CARGO’s public filings and press releases consistently characterize it as a clinical-stage biotechnology company with programs, platform technologies, and manufacturing strategy aimed at improving the performance and availability of cell therapies.

Core programs and therapeutic focus

CARGO’s lead program was firicabtagene autoleucel (firi-cel, also referenced as CRG-022), described as an autologous CD22 chimeric antigen receptor (CAR) T‑cell therapy candidate. Company communications state that firi-cel was evaluated in a potentially pivotal Phase 2 clinical study (FIRCE‑1) in patients with large B‑cell lymphoma (LBCL) whose disease relapsed or was refractory to CD19 CAR T‑cell therapy. CARGO reported that it exclusively in‑licensed the underlying CD22 CAR T‑cell technology from the National Cancer Institute and that Phase 1 data generated at Stanford Medicine supported further development.

Beyond its lead program, CARGO described a pipeline built on proprietary cell‑engineering platform technologies that incorporate multiple transgene therapeutic “cargo” to enhance CAR T‑cell persistence, trafficking to tumor lesions, and to help safeguard against tumor resistance and T‑cell exhaustion. This approach is highlighted in repeated company descriptions and forms the conceptual basis for its name and pipeline strategy.

A key pipeline asset was CRG‑023, which CARGO characterized as a CD19/CD20/CD22 tri‑specific CAR T product candidate. Company materials describe CRG‑023 as a first‑of‑its‑kind tri‑cistronic CAR T designed to express three independent CARs from a single vector, each with its own co‑stimulatory domain, including CD2 co‑stimulation. According to the company, CRG‑023 is intended to address several known causes of relapse associated with existing CAR T‑cell therapies, such as tumor antigen loss, loss of co‑stimulation and T‑cell exhaustion, with the goal of providing more patients with durable responses across a broad range of B‑cell malignancies.

CARGO also disclosed development of a novel allogeneic platform, described as a universal vector solution designed to limit immune‑based rejection and enable durable response of CAR T‑cell therapy. Company statements explain that this allogeneic‑enabling vector is intended to be paired with new or existing CAR vectors to create allogeneic CAR T‑cell therapies while leveraging existing autologous drug product processes, with the aim of maintaining efficacy, durability and safety while broadening availability to more people with cancer.

Scientific and operational capabilities

Across its public communications, CARGO emphasized its proprietary cell‑engineering platform technologies and internally developed processes and analytical methods. It highlighted capabilities in designing, developing and delivering oncology and cell therapy products, including manufacturing strategies intended to provide predictable and reliable drug product supply. The company reported strong manufacturing success for firi‑cel in its clinical program and described its lentiviral vector production for CRG‑023 as using a suspension culture process with a line of sight to commercially suitable expression levels.

CARGO also noted that its leadership, founders and team have significant experience in developing, engineering, manufacturing, launching and commercializing oncology and cell therapy products. The company repeatedly referenced expertise in CAR T‑cell therapy, including the use of multiple transgene “cargo” to enhance CAR T‑cell performance and to address mechanisms such as tumor resistance, T‑cell exhaustion, and immune‑based rejection.

Corporate status, merger and delisting

CARGO Therapeutics, Inc. was listed on The Nasdaq Stock Market LLC under the symbol CRGX. According to a Form 8‑K dated August 19, 2025, CARGO entered into an Agreement and Plan of Merger with Concentra Biosciences, LLC and Concentra Merger Sub VII, Inc. and completed a tender offer followed by a merger. The filing states that on August 19, 2025, Merger Sub merged with and into CARGO, with CARGO continuing as the surviving corporation and becoming a wholly owned subsidiary of Concentra.

The same Form 8‑K reports that, in connection with the consummation of the offer and merger, CARGO notified Nasdaq of the merger and requested suspension of trading of its common stock and the filing of a Form 25 to effect delisting and deregistration under Section 12(b) of the Exchange Act. A subsequent Form 25 (Form 25‑NSE) filed by Nasdaq identifies CARGO Therapeutics, Inc. and its common stock and serves as notification of removal from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934.

Following the Form 25, CARGO filed a Form 15‑12G, certifying termination of registration under Section 12(g) and suspension of duty to file reports under Sections 13 and 15(d) of the Exchange Act. The Form 15 notes that the approximate number of holders of record as of the certification date was one, consistent with CARGO’s status as a wholly owned subsidiary after completion of the merger.

These filings together indicate that CRGX has been delisted from Nasdaq and deregistered with the SEC as a reporting company, and that public reporting obligations for the common stock have been suspended. The ticker CRGX therefore represents a defunct public listing that historically corresponded to CARGO Therapeutics, Inc. prior to its acquisition by Concentra Biosciences.

Strategic review and pipeline changes prior to acquisition

Before the completion of the merger, CARGO disclosed a series of strategic shifts. In a March 18, 2025 corporate update, the company announced the discontinuation of the FIRCE‑1 Phase 2 study of firi‑cel and stated that its board had concluded it was in the best interests of shareholders to cease development operations. The same update reported suspension of development efforts for CRG‑023 and the allogeneic platform, along with a significant reduction in workforce and an intent to pursue a reverse merger or other business combination.

Earlier, on January 29, 2025, CARGO had announced its decision to discontinue FIRCE‑1 based on an ad hoc analysis of safety and efficacy data, while at that time indicating plans to continue advancing CRG‑023 and the allogeneic platform and to evaluate strategic options. Subsequent communications, including the March 18, 2025 update, clarified that development operations across these programs were being halted as part of a broader strategic review.

Historical context for investors and researchers

For investors, clinicians, and researchers reviewing CRGX as a historical listing, CARGO Therapeutics represents a case of a clinical‑stage biotechnology company that advanced differentiated CAR T‑cell and allogeneic platform concepts, conducted clinical and preclinical work in B‑cell malignancies, and then transitioned through a strategic review, suspension of development, and ultimately an acquisition by Concentra Biosciences. Its SEC filings and press releases provide a detailed record of its scientific rationale, clinical program design, and corporate actions leading up to its delisting and deregistration.

Last Close
$4.47
EPS (FY2024)
-$3.72
View full CRGX overview

Frequently Asked Questions

CARGO Therapeutics, Inc. investment returns

How much was $1,000 invested in CARGO Therapeutics, Inc. worth at its last close?

If you invested $1,000 in CARGO Therapeutics, Inc. (CRGX) 1 year before its last close, on 2024-08-19, your investment was worth $255 on 2025-08-18, a -74.5% price return without dividends.

Has CARGO Therapeutics, Inc. outperformed the S&P 500?

Comparison data requires at least 10 years of trading history. Use the calculator above to compare CRGX performance over available time periods.

What is CARGO Therapeutics, Inc.'s average annual return?

Over the 1 year to Aug 18, 2025, CRGX’s share price returned -74.5%, without dividends. Individual years vary a great deal, and CRGX’s best recent full year was 2024 (-37.7%) while the worst was 2024 (-37.7%).

For informational and educational purposes only, not investment advice.